Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

44806 ARTÍCULOS , VIENDO DEL 1606 AL 1620

Systematic Review of the Huntington's Disease Drug Development Pipeline, 2014 to 2025

Konstantinova P, Townhill J, Bronzova J, Andreeva V, Sathe S, Sampaio C.

Mov Disord. 2026 Jun 1. doi: 10.1002/mds.70361. Online ahead of print.

Targeting mitophagy for neuroprotection: mechanisms and therapeutic opportunities

Yang J, Li J, Hou X, Zheng Y, Zhao Z, Zhou T, Jing T, Kong J, Zhang G, Guo Y.

NPJ Aging. 2026 Jun 3. doi: 10.1038/s41514-026-00424-3. Online ahead of print.

Molecular interplay between Non-coding RNAs and BDNF in Neurodegenerative Disorders: a systematic review

Jalaiei A, Kiani Darabi AH, Sakkaki E, Rezazadeh M, Ghafouri-Fard S.

Mol Biol Rep. 2026 Jun 6;53(1):901. doi: 10.1007/s11033-026-12067-4.

Nanotechnology-enabled targeting strategies for neurodegenerative disorders: role of functionalized nanoparticles

Vishwakarma H, Chauhan A, Kaur L, Awasthi A.

J Pharm Pharmacol. 2026 Jun 2;78(6):rgag060. doi: 10.1093/jpp/rgag060.

Mitochondrial Dysfunction as a Driver of Neurodegeneration in Parkinson's and Huntington's Disease: Molecular Insights and Emerging Interventions

Kuwar OK, Khan S, Maloo A, Singh C, Sharma M, Maparu K, Dhingra MS, Sharma V.

Mol Neurobiol. 2026 Jun 10;63(1):685. doi: 10.1007/s12035-026-05991-w.

Naringenin as a multi-target neuroprotective agent in neurodegenerative diseases

Gurung N, Choi DY, Park PH.

Neurochem Int. 2026 Sep;198:106203. doi: 10.1016/j.neuint.2026.106203. Epub 2026 Jun 11.

Histological and Tissue-Level Outcomes of Stem Cell Therapies in Neurodegenerative Disorders: A Systematic Review

Fikry H, Saleh LA, Sadek DR.

Clin Anat. 2026 Jun 12. doi: 10.1002/ca.70147. Online ahead of print.

Focused ultrasound-mediated nanocarrier delivery across the blood-brain barrier for neurodegenerative diseases

Jaberi KR, Haghighi MR, Aligholi H, Takallu S, Asadi P, Mirzaei E, Jaberi AR, Sahraian A.

Biomed Pharmacother. 2026 Aug;201:119622. doi: 10.1016/j.biopha.2026.119622. Epub 2026 Jun 13.

GLP-1 Receptor Agonists in Neurological Disorders: From Mechanisms to Clinical Translation

Li P, Gao Y, Liu W.

Drug Des Devel Ther. 2026 Jun 12;20:613616. doi: 10.2147/DDDT.S613616. eCollection 2026.

Exercise-Driven NRF2 Activation as a Systemic Neuroprotective Strategy: Integrating Redox Biology, Muscle-Brain Crosstalk, and Therapeutic Targeting in Neurodegeneration

Deng P, Deng W, Wang L, Ye W, Li S.

Biochem Genet. 2026 Jun 18. doi: 10.1007/s10528-026-11415-0. Online ahead of print.

Microglia-driven neuroinflammatory signaling in neurodegeneration: mechanisms and therapeutic opportunities

Saini K, Dhiman P.

Mol Biol Rep. 2026 Jun 18;53(1):941. doi: 10.1007/s11033-026-12128-8.

Electroconvulsive Therapy in Movement Disorders: A Systematic Review

Kindts L, Bouillon K, Sienaert P.

J ECT. 2026 Jun 23. doi: 10.1097/YCT.0000000000001225. Online ahead of print.

N-terminal modifications as fate switches in neurodegeneration: a mechanistic review

Mukherjee D, Raghul Kannan S, Tamizhselvi R.

Front Aging Neurosci. 2026 Jun 5;18:1809812. doi: 10.3389/fnagi.2026.1809812. eCollection 2026.

Glucagon-like peptide-1 receptor agonists in movement disorders: From Parkinson's disease to the broader spectrum - Mechanisms, evidence, and future directions

Dahshan A, Khalil MIM, El-Jaafary SI, Al Yamani A.

Clin Park Relat Disord. 2026 Jun 3;15:100461. doi: 10.1016/j.prdoa.2026.100461. eCollection 2026.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias